Search
Displaying 841–850 of 1144 results
-
Thank you for signing up!
-
ARVO 2019: Emerging Eloxx Molecules Show Promising Results in Usher Models
Research NewsEloxx Pharmaceuticals is developing small molecules that permit read-through of point mutations that cause Usher syndrome 1F and 2A.
-
ARVO 2019: Emerging Drug for RP Evaluated in Safety & Tolerability Study
Research NewsFrancois Paquet-Durand, PhD, chief scientific officer at the company Mireca, discusses an emerging drug for retinitis pigmentosa, and other inherited retinal diseases.
-
Communication subscription information update page.
-
REGENXBIO’s Gene Therapy for Wet AMD Performing Encouragingly in Human Study
Research NewsUnlike current treatments requiring multiple injections, REGENXBIO’s gene therapy is administered as a one-time subretinal injection to the affected eye.
-
Find out where your donation dollars go.
-
ARVO 2019 Highlight: RP Patients in ReNeuron’s Cell Therapy Trial Show Further Vision Improvements
Research NewsThe latest ReNeuron results were presented at the sixth annual Retinal Cell and Gene Therapy Innovation Summit held on April 26 in Vancouver, Canada.
